The ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing, compared to the broader index which is up by 0.55%.

OncoSil Medical (ASX:OSL) has released the final results of the PanCO clinical study for the treatment of advanced pancreatic cancer.

The full paper was published in ESMO Open, the European Society for Medical Oncology’s peer-reviewed journal dedicated to publishing high-quality medical research.

Conducted at ten specialist centres in Australia, Belgium and the UK, the study demonstrated that lead drug OncoSil had an acceptable safety profile when added to standard-of-care chemotherapy.

The study concluded there was no evidence of severe adverse events after the implantation of OncoSil.

Shares in the company jumped by almost 20% at the opening bell.


OncoSil share price today:




Other ASX health stocks news this morning

Neuroscientific Biopharma (ASX:NSB) released positive results from the recently completed off-target safety assessment of its lead drug candidate, EmtinB.

Off-target safety assessments help to identify unintended interactions between a drug and a host of biological targets that are known to cause adverse side effects and toxicities in humans.

The assessment involved a comprehensive in-vitro screening program prior to the first-in-human Phase I clinical study, which is expected to commence in the first half of 2022.

Imricor Medical Systems (ASX:IMR) has signed up two new German institution customers to adopt Imricor’s iCMR ablation solutions.

The German Heart Centre Berlin and the Charité Medical University have both signed up, bringing the total number of Imricor sites to thirteen.

For the German Heart Centre, Imricor will outfit an existing CMR facility for iCMR procedures. Both institutions will then utilise the iCMR lab at the Heart Centre.

The agreement is significant as it is a key strategic goal of Imricor to grow the number of sites performing realtime iCMR cardiac ablation procedures in Europe.

Universal Biosensors (ASX:UBI) has entered into a global exclusive license deal with IQ Science, for the commercialisation of a SARS-CoV-2 N-Protein detection test.

The COVID-19 test will use UBI’s proprietary electrochemical strip and device technology, designed to provide a positive or negative result as to a patient’s viral status within 30 seconds, from just a small saliva sample.

UBI says its electrochemical test method also has the potential to measure the relative viral load associated with a patient’s infection status.

The license agreement could potentially see UBI earn fees when sales of the COVID- 19 test have reached $1 million.



Share prices today: